layoffs
Vertex Lays Off 125 Staffers, Shrinks Rhode Island Campus After Diabetes Therapy Setback
Vertex Pharmaceuticals; layoffs; Rhode Island; diabetes therapy; VX-264; cell-device combo; clinical trial failure; facility consolidation
Recursion Pharmaceuticals Lays Off 20% of Staff Amid Pipeline Cutbacks
Recursion Pharmaceuticals; layoffs; pipeline cutbacks; biotech; workforce reduction; restructuring; rare diseases; oncology
Keros Therapeutics Halts Pulmonary Hypertension Drug After Safety Issues, Cuts 45% of Workforce
Keros Therapeutics; cibotercept; pulmonary arterial hypertension; PAH; layoffs; pericardial effusion; drug development halt; cost savings; biotech sector
Boundless Bio Lays Off 33% of Staff Following Stumble of Lead Program
Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring
Prothena Halts Drug and Plans Major Layoffs After Second Rare Disease Trial Failure
Prothena; birtamimab; AL amyloidosis; Phase III trial; drug failure; layoffs; biotech; spending cuts; business options
About 5% of CBER and CDER Left After FDA Staff Cuts, Analysis Finds
FDA layoffs; CBER; CDER; drug review; biologics; staff cuts; Trump administration; drug approval process
Eikon Therapeutics Implements Second Major Staff Reduction in Under Two Years
Eikon Therapeutics; layoffs; biotech; staff cuts; funding cuts; research instrument development; workforce reduction; Roger Perlmutter
Korro Bio Lays Off 20% of Workforce to Extend Runway for Genetic Medicine Trials and Novo Nordisk Partnership
Korro Bio; layoffs; biotech; genetic medicine; RNA editing; KRRO-110; Novo Nordisk; clinical trial funding; restructuring; AATD
Schrödinger Lays Off 60 Staffers Amid Economic Uncertainty
Schrödinger; layoffs; biotech; workforce reduction; economic conditions; cost cutting; restructuring
Prime Medicine CEO Exits Amidst Layoffs and Restructuring as Sole Clinical Gene Therapy Shelved
Prime Medicine; CEO exit; gene therapy; layoffs; restructuring; biotech; PM359; prime editing; clinical trial; pipeline pivot